Invention Grant
US08722049B2 Antibody and methods for selective inhibition of T-cell responses
有权
用于选择性抑制T细胞应答的抗体和方法
- Patent Title: Antibody and methods for selective inhibition of T-cell responses
- Patent Title (中): 用于选择性抑制T细胞应答的抗体和方法
-
Application No.: US13930757Application Date: 2013-06-28
-
Publication No.: US08722049B2Publication Date: 2014-05-13
- Inventor: Daniel R Getts , James J Herrmann , John J Puisis , Frank J Fokta
- Applicant: Tolera Therapeutics, Inc
- Applicant Address: US MI Kalamazoo
- Assignee: Tolera Therapeutics, Inc.
- Current Assignee: Tolera Therapeutics, Inc.
- Current Assignee Address: US MI Kalamazoo
- Agency: Cooley LLP
- Main IPC: A61K39/395
- IPC: A61K39/395
Abstract:
The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided. The present invention also provides methods of treating inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using a therapeutic amount of ex vivo expanded regulatory T-cells.
Public/Granted literature
- US20130302301A1 ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES Public/Granted day:2013-11-14
Information query
